# A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

> **NCT03257631** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 53 (actual)

## Conditions studied

- Central Nervous System Neoplasms
- Medulloblastoma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT03257631
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257631, "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03257631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*